Compugen Doses First Patient In Triple Immunotherapy Combination COM701, COM902 And Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Study
Portfolio Pulse from Bill Haddad
Compugen has dosed its first patient in a proof-of-concept study for a triple immunotherapy combination of COM701, COM902, and Pembrolizumab in platinum-resistant ovarian cancer patients.
June 22, 2023 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Compugen's initiation of a proof-of-concept study for its triple immunotherapy combination may positively impact its stock price in the short term.
The initiation of the proof-of-concept study for Compugen's triple immunotherapy combination indicates progress in the company's research and development efforts. This news may be seen as a positive development by investors, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100